Chlorpheniramine

Selected References:

- Aldridge TD, et al. 2014. First-trimester antihistamine exposure and risk of spontaneous abortion or preterm birth. Pharmacoepidemiol Drug Saf, 23(10):1043-50.
- Aselton P, et al. 1985. First-trimester drug use and congenital disorders. Obstet Gynecol 65(4):451-455.
- Diav-Citrin O, et al. 2003. Pregnancy outcome after gestational exposure to loratadine or antihistamines: a prospective controlled cohort study. J Allergy Clin Immunol 111(6):1239-1243.
- Etwel F, et al. 2017. The Risk of Adverse Pregnancy Outcome After First Trimester Exposure to H1 Antihistamines: A Systematic Review and Meta-Analysis. Drug Saf, 40(2):121-132.
- Gilboa SM, et al. 2014. Antihistamines and birth defects: a systematic review of the literature. Expert Opin Drug Saf, 13(12):1667-98.
- Gilboa SM, et al. 2009. National Birth Defects Prevention Study: Use of antihistamine medications during early pregnancy and isolated major malformations. Birth Defects Res A Clin Mol Teratol 85(2):137-150.
- Hansen C, et al. 2020. Use of antihistamine medications during early pregnancy and selected birth defects: The National Birth Defects Prevention Study, 1997-2011. Birth Defects Res, 112(16):1234-1252.
- Hellbom E. 2005. Chlorpheniramine, selective serotonin-reuptake inhibitors (SSRIs) and over-the-counter (OTC) treatment. Med Hypotheses. ;66(4):689-90.
- Ito S, et al. 1993. Prospective follow-up of adverse reactions in breastfed infants exposed to maternal medication. Am J Obstet Gynecol. 168:1393-1399.
- Jick H, et al. 1981: First-trimester drug use and congenital disorders. JAMA 246(4):343-346.
- Koh YP, et al. 2019. New Change in pregnancy and lactation labeling: Review of dermatologic drugs. Int'l J of Women's Dermatology, 5(4):216-226
- Li Q et al. 2013. Assessment of antihistamine use in early pregnancy and birth defects. J Allergy Clin Immunol Pract. 1(6):666-74.
- Nelson MM and Forfar JJ. 1971. Associations between drugs administered during pregnancy and congenital abnormalities of the fetus. Br Med J. 1;523-527.
- Ngo E, et al. 2022. Antihistamine use during breastfeeding with focus on breast milk transfer and safety in humans: A systematic literature review. Basic Clin Pharmacol Toxicol, 130(1):171-181.

Descargo de responsabilidad: las hojas informativas de MotherToBaby están destinadas a fines de información general y no deben reemplazar los consejos de su proveedor de atención médica. MotherToBaby es un servicio de la Organización sin fines de lucro de Especialistas en Información de Teratología (OTIS). Copyright de OTIS, 1 de enero de 2025.

Chlorpheniramine

Selected References:

- Arango O, et al. 1996. Reversible azoospermia in a patient treated with triazolam. Eur J Contracept Reprod Health Care; 1:293-4.
- Bagger NT, et al. 2023. Perinatal outcomes after therapeutic rest in the latent phase of labor: A cohort study. Acta obstetricia et gynecologica Scandinavica, 102(9), 1210–1218.
- Halcion Prescribing Information. Available online at https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/017892s049lbl.pdf. [Accessed Jan 2025]
- Kallen B, et al. 2013. The use of central nervous system active drugs during pregnancy. Pharmaceuticals 6(10):1221-1286.
- Kelly LE, et al. 2012. Neonatal benzodiazepines exposure during breastfeeding. J Pediatr; 161(3):448-51.
- Matsuo A, et al. 1979. Reproduction studies of triazolam in rats and rabbits. Iyakuhin Kenkyu 10:52-67.
- Noh Y, et al. 2022. First-trimester exposure to benzodiazepines and risk of congenital malformations in offspring: A population-based cohort study in South Korea. PLoS Med; 19(3):e1003945.
- Sakai T, et al. 1996. Triazolam (Halcion) intoxication in a neonate–a first report [letter]. Eur J Pediatr; 155:1065-6.

Descargo de responsabilidad: las hojas informativas de MotherToBaby están destinadas a fines de información general y no deben reemplazar los consejos de su proveedor de atención médica. MotherToBaby es un servicio de la Organización sin fines de lucro de Especialistas en Información de Teratología (OTIS). Copyright de OTIS, 1 de enero de 2025.

Chlorpheniramine

Selected References:

- Aselton P, et al. 1984. First-trimester drug use and congenital disorders. Obstet Gynecol,65(4):451- 455.
- Brigstocke S, et.al 2022. Review of the Safety Profiles of Laxatives in Pregnant Women. J Clin Gastroenterol, 56(3):197-203.
- Greenhalf JO, Leonard HS. 1973. Laxatives in the treatment of constipation in pregnant and breast-feeding mothers. Practitioner; 210:259-63.
- Hale, TW. 2012. Medications and Mothers' Milk. Fifteenth Edition. Amarillo, TX: Hale Publishing L.P.
- Heinonen OP, et al. 1977. Birth Defects and Drugs in Pregnancy. Littleton, Mass.: John Wright-PSG, pp 385, 442.
- Jick H, et al. 1981. First-trimester drug use and congenital disorders. JAMA,246(4):343-346.
- Laden S. 2019. OTC Medication Use in Pregnancy and Breastfeeding. US Pharmacist, 44(9):16-19
- Lameris AL, et al. 1979. Drug induced alterations in Mg2+ homeostasis. Clinical Science,123(1):1.
- MacKenzie K, et al. 1990. Three-generation reproduction study with dioctyl sodium sulfosuccinate in rats. Fundam Appl Toxicol,15:53-62.
- Mahadevan U, & Kane S. 2006. American Gastroenterological Association Institute technical review on the use of gastrointestinal medications in pregnancy. Gastroenterology,131(1):283-311.
- Rungsiprakarn P, et al. 2015. Interventions for treating constipation in pregnancy. Cochrane Database Syst Rev, Sep 4;2015(9):CD011448
- Schindler AM. 1984. Isolated neonatal hypomagnesaemia associated with maternal overuse of stool softener. Lancet,2:822.
- Thorpe PG, et al. 2013. Medications in the first trimester of pregnancy: most common exposures and critical gaps in understanding fetal risk. Pharmacoepidemiol Drug Safe, 22(9): 1013-1018.
- Zielinski R, et al. 2015. Gastrointestinal distress in pregnancy: prevalence, assessment, and treatment of 5 common minor discomforts. J Perinat Neonatal Nurs, 29(1):23-31.

Descargo de responsabilidad: las hojas informativas de MotherToBaby están destinadas a fines de información general y no deben reemplazar los consejos de su proveedor de atención médica. MotherToBaby es un servicio de la Organización sin fines de lucro de Especialistas en Información de Teratología (OTIS). Copyright de OTIS, 1 de enero de 2025.

Chlorpheniramine

Selected References:

- American Academy of Pediatrics. 2008. Maternal phenylketonuria. Committee on Genetics. Pediatrics;122:445–9.
- American College of Obstetricians and Gynecologists Committee on Genetics. 2020. ACOG Committee Opinion 802: Management of Women With Phenylalanine Hydroxylase Deficiency (Phenylketonuria). Obstet Gynecol. 135(4):e167-e170.
- Aldámiz-Echevarría L,et al. 2014. A new case of maternal phenylketonuria treated with sapropterin dihydrochloride. Gynecol Endocrinol. 13:1-3.
- Banta-Wright SA, et al. 2014. Breastfeeding infants with phenylketonuria in the United States and Canada. Breastfeeding Medicine, 9(3), 142-148.
- Burgard P, et al. 1997. Neuropsychologic functions of early treated patients with phenylketonuria, on and off Diet: Results of a cross-national and cross-sectional study. Pediatr Res 41(3):368-374.
- Camp KM, et al. 2014. Phenylketonuria Scientific Review Conference: state of the science and future research needs. Mol Genet Metab. 112(2):87-122.
- Cetin I, et al. 1990. Umbilical amino acid concentration in normal and growth-retarded fetuses sampled in utero by cordocentesis. Am J Obstet Gynecol; 162(1):253–261.
- Feillet F, et al. 2014. Use of sapropterin dihydrochloride in maternal phenylketonuria. A European experience of eight cases.J Inherit Metab Dis.
- Fisch RO, et al. 1991. Children of fathers with phenylketonuria: An international survey. J Pediatr 118(5): 39-741.
- Fox-Bacon C, et al. 1997. Maternal PKU and breastfeeding: case report of identical twin mothers. Clin Pediatr 36(9):539-542.
- Grange DK,et al. 2014. Sapropterin dihydrochloride use in pregnant women with phenylketonuria: an interim report of the PKU MOMS sub-registry. Phenylketonuria Demographics Outcomes and Safety (PKUDOS) registry; Maternal Phenylketonuria Observational Program (PKU MOMS) sub-registry. Mol Genet Metab. 112(1):9-16.
- Grohmann-Held K, et al. 2022. Impact of pregnancy planning and preconceptual dietary training on metabolic control and offspring's outcome in phenylketonuria. J Inherit Metab Dis; 45(6): 1070- 1081.
- Güttler F, et al. 1990. Cognitive development in offspring of untreated and preconceptionally treated maternal phenylketonuria. J Inherit Metab Dis. 13(4):665-71.
- Kenneson A, Borth MI, et al. 2024. Characteristics and outcomes of pregnancies among women with phenylketonuria from the NBS Connect registry. Mol Genet Metab Rep; 39:101092.
- Koch R, et al. 2003. The Maternal Phenylketonuria International Study: 1984–2002. Pediatrics 112(suppl): 1523-1529.
- Koch R, el al. 2005. Tetrahydrobiopterin and maternal PKU. Mol Gen Met 86: S139-S141.
- Koch R, et al. 2010. Psychosocial issues and outcomes in maternal PKU. Mol Genet Metab. 99 Suppl 1:S68-74.
- Kose E, et al. 2017. The effects of breastfeeding in infants with Phenylketonuria. J Pediatr Nurs; 38:27-32.
- Lenke RR and Levy HL. 1980. Maternal phenylketonuria and hyperphenylalanemia: An international survey of the outcome of untreated and treated pregnancies. NEJM 303(21):1202-1208.
- Levy HL, et al. 1991. Paternal phenylketonuria. J Pediatr 118(5):741-743.
- Levy HL, et al. 1996. Fetal ultrasonagraphy in maternal PKU. Prenat Diagn 16:599-604.
- Levy HL & Ghavami M. 1996. Maternal phenylketonuria: a metabolic teratogen. Teratology. 53(3):176-84.
- Lichter-Konecki, U, et al. 2019. Phenylketonuria: Current Treatments and Future Developments. Drugs 79,

495–500

- Maillot, F, et al. 2007. A practical approach to maternal phenylketonuria management. J Inherit Metab Dis. 30, 198–201.
- Michals-Matalon K et al. 2003. Role of nutrition in pregnancy with phenylketonuria and birth defects. Pediatrics 112(suppl): 1534-1536.
- Nielsen MR, Jørgensen C, et al. 2023. The impact of phenylalanine levels during pregnancy on birth weight and later development in children born to women with phenylketonuria. J Inherit Metab Dis; 46(4):586-594.
- Platt LD, et al. 2000. The international study of pregnancy outcome in women with maternal phenylketonuria: report of a 12-year study. American journal of obstetrics and gynecology, 182(2), 326-333.
- Prick BW, et al. 2012. Maternal phenylketonuria and hyperphenylalaninemia in pregnancy: pregnancy complications and neonatal sequelae in untreated and treated pregnancies. Am J Clin Nutr 95:374–382.
- Rouse B, et al. 1997. Maternal phenylketonuria Collaborative Study (MPUCS) offspring: Facial anomalies, malformations, and early neurological sequelae. Am J Med Genet 69:89-95.
- Rouse B & Azen C. 2004. Effect of high maternal blood phenylalanine on offspring congenital anomalies and developmental outcome at ages 4 and 6 years: the importance of strict dietary control preconception and throughout pregnancy. J Pediatr 144:235–239.
- Schmidt E, et al. 1994. Sustained attention in adult phenylketonuria: the influence of the concurrent phenylalanine-blood level. J Clin Exp Neuropsych 16(5):681-688.
- Singh RH, et al. 2014. Recommendations for the nutrition management of phenylalanine hydroxylase deficiency. Genet Med 16:121–123.
- Smith WE, Berry SA, et al. 2025. Phenylalanine hydroxylase deficiency diagnosis and management: A 2023 evidence-based clinical guideline of the American College of Medical Genetics and Genomics (ACMG). ***Genet*** Med; 27(1):101289.
- Teissier R, et al. 2012. Maternal phenylketonuria: low phenylalaninemia might increase the risk of intra uterine growth retardation. AFDPHE (Association Française pour le Dépistage et la Prévention des Handicaps de l'Enfant). J Inherit Metab Dis ;35:993–9.
- Trefz FK, et al. 2003. Potential role of tetrahydrobiopterin in the treatment of maternal phenylketonuria. Pediatrics 112(suppl): 1566-1569.
- Van Rijn M, et al. 2003. A different approach to breast-feeding of the infant with phenylketonuria. Eur J Pediatr 162:323-326.
- van Wegberg, A.M.J., et al. 2017. The complete European guidelines on phenylketonuria: diagnosis and treatment. Orphanet J Rare Dis (12) 162.
- Vockley J, et al. 2014. Phenylalanine hydroxylase deficiency: diagnosis and management guideline. Genetics in Medicine, 16(2), 188.
- Waisbren SE, et al. 2014. Maternal phenylketonuria: long-term outcomes in offspring and post-pregnancy maternal characteristics. In JIMD Reports, Volume 21 (pp. 23-33).
- Wambach K & Riordan J. 2016. Breastfeeding and human lactation. Jones & Bartlett Learning.
- Weglage J, et al. 2001. Normal clinical outcome in untreated subjects with mild hyperphenylalaninemia. Pediatr Res 49:532–536.
- Widaman KF, Azen C. 2003. Relation of prenatal phenylalanine exposure to infant and childhood cognitive outcomes: results from the International Maternal PKU Collaborative Study. Pediatrics;112:1537–43.

Descargo de responsabilidad: las hojas informativas de MotherToBaby están destinadas a fines de información general y no deben reemplazar los consejos de su proveedor de atención médica. MotherToBaby es un servicio de la Organización sin fines de lucro de Especialistas en Información de Teratología (OTIS). Copyright de OTIS, 1 de enero de 2025.

Chlorpheniramine

Selected References:

- Alsenaid A, Prinz JC. 2016. Inadvertent pregnancy during ustekinumab therapy in a patient with plaque psoriasis and impetigo herpetiformis. J Eur Acad Dermatol Venereol. 30(3):488-90.
- American Academy of Pediatrics. 2018. Report of the Committee of Infectious Disease. RedBook. p704.
- Andrulonis R, Ferris LK. 2012 Treatment of severe psoriasis with ustekinumab during pregnancy. J Drugs Dermatol. 11(10):1240.
- Avni-Biron, I.,et al. 2022. Ustekinumab during pregnancy in patients with inflammatory bowel disease: a prospective multicentre cohort study. Alimentary pharmacology & therapeutics, 56(9), 1361–1369.
- Beaulieu D, et al. 2018. Use of Biologic Therapy by Pregnant Women with Inflammatory Bowel Disease does Not affect Infant Response to Vaccines. Clin Gast & Hep; 16:99-105.
- Chaparro Sanchez M, et al. 2022. Live vaccines in children exposed to biological agents for IBD in utero and/or during breastfeeding: Are they safe? Results from the Dumbo registry of GETECCU. United European Gastroenterol J 2022;10:757-8.
- Chugh, R., et al. 2024. Maternal and Neonatal Outcomes in Vedolizumab- and Ustekinumab-Exposed Pregnancies: Results From the PIANO Registry. The American journal of gastroenterology, *119*(3), 468–476.
- Ernest-Suarez, K., et al. 2024. Live Rotavirus Vaccination Appears Low-risk in Infants Born to Mothers With Inflammatory Bowel Disease on Biologics. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, S1542-3565(24)00677-3.
- Fitzpatrick, T., et al. 2023. Immunological effects and safety of live rotavirus vaccination after antenatal exposure to immunomodulatory biologic agents: a prospective cohort study from the Canadian Immunization Research Network. The Lancet. Child & adolescent health, 7(9), 648–656.
- Fotiadou C, et al. 2012. Spontaneous abortion during ustekinumab therapy. J Dermatol Case Rep. 6(4):105-107.Galli-Novak E, et al. 2016. Successful pregnancy outcome under prolonged ustekinumab treatment in a patientwith Crohn’s disease and paradoxical psoriasis. J Eur Acad Dermatol Venereol. 30(12):e191-e192.
- Galluzzo M, et al. 2019. Psoriasis in pregnancy: case series and literature review of data concerning exposure during pregnancy to ustekinumab. J Dermatolog Treat. 2019 Feb;30(1):40-44.
- Gisbert J, Chaparro M. 2020. Safety of New Biologics (Vedolizumab and Ustekinumab) and Small Molecules (Tofacitinib) During Pregnancy: A Review. Drugs 2020 Jul; 80(11):1085-1100.
- Gorodensky, J. H., Bernatsky, S., Afif, W., St-Pierre, Y., Filion, K. B., & Vinet, É. (2023). Assessing Serious Infections in Children Exposed In Utero to Ustekinumab. The Journal of rheumatology, jrheum.2022-1271.
- Gotestam Skorpen C, et al. 2016. The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann Rheum Dis. 75:795-810.
- Grosen, A., et al. 2022. Normal Sperm DNA Integrity in Patients With Inflammatory Bowel Disease on

Ustekinumab Maintenance Therapy. Inflammatory bowel diseases, *28*(10), 1603–1606.

- Jeong, Y. D. et al. 2024. Biologics Use for Psoriasis during Pregnancy and Its Related Adverse Outcomes in Pregnant Women and Newborns: Findings from WHO Pharmacovigilance Study. International archives of allergy and immunology, 1–15.
- Julsgaard, M., et al. 2025. Infant Ustekinumab Clearance, Risk of Infection, and Development After Exposure During Pregnancy. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, *23*(1), 134–143.
- Klenske E, et al. 2019. Drug Levels in the Maternal Serum, Cord Blood and Breast Milk of a Ustekinumab-Treated Patient with Crohn's Disease. J Crohns Colitis. 2019 Feb 1;13(2):267-269.
- Lund T and Thomsen SF. 2017. Use of TNF-inhibitors and ustekinumab for psoriasis during pregnancy: a patient series. Dermatologic Therapy 30:e12454.
- Mahadevan U, et al. 2017. Drug Safety and Risk of Adverse Outcomes for Pregnant Patients With Inflammatory Bowel Disease. Gastroenterology. 152(2):451-462.e2.
- Mahadevan U, et al. 2019. Inflammatory Bowel Disease in Pregnancy Clinical Care Pathway: A Report From the American Gastroenterological Association IBD Parenthood Project Working Group. Amer J of Obstetrics and Gynecology. 2019 April; 220(4):308-323.
- Mahadevan, U., et al. 2022. Pregnancy outcomes following periconceptional or gestational exposure to ustekinumab: Review of cases reported to the manufacturer's global safety database. *Alimentary pharmacology & therapeutics*, *56*(3), 477–490. https://doi.org/10.1111/apt.16960
- Martin PL, et al. 2010. Development in the cynomolgus macaque following administration of ustekinumab, a human anti-IL-12/23p40 monoclonal antibody, during pregnancy and lactation. Birth Defects Res B Dev Reprod Toxicol. 89(5):351-363.
- Matro R, et al. 2018. Exposure concentrations of infants breastfed by women receiving biologic therapies for inflammatory bowel disease and effects of breastfeeding on infections and development. Gastroenterology 155;696-704.
- Meserve, J., 2021. Paternal Exposure to Immunosuppressive and/or Biologic Agents and Birth Outcomes in Patients With Immune-Mediated Inflammatory Diseases. Gastroenterology, 161(1), 107–115.e3.
- Meyer, A., et al. 2025. Safety of Vedolizumab and Ustekinumab Compared With Anti-TNF in Pregnant Women With Inflammatory Bowel Disease. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, *23*(1), 144–153.e22.
- Mitrova, K., et al. 2022. Safety of Ustekinumab and Vedolizumab During Pregnancy-Pregnancy, Neonatal, and Infant Outcome: A Prospective Multicentre Study. Journal of Crohn's & colitis, *16*(12), 1808–1815.
- Prentice, R., et al. 2025. Vedolizumab and Ustekinumab Levels in Pregnant Women With Inflammatory Bowel Disease and Infants Exposed In Utero. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, *23*(1), 124–133.e7
- Rocha K, et al. 2015. Pregnancy during ustekinumab treatment for severe psoriasis. Dermatology; 231:103-104.
- Rosen M, et al. 2012. A case of ustekinumab for the treatment of Crohn's disease during pregnancy [abstract]. Amer J Gastroenterol. 107(suppl 1):S516.
- Rowan CR, et al. 2018. Ustekinumab drug levels in maternal and cord blood in a woman with Crohn's Disease treated until 33 weeks of gestation. Journal of Crohn's and Colitis;376-378
- Sánchez-García, V., et al. 2023. Exposure to biologic therapy before and during pregnancy in patients with psoriasis: Systematic review and meta-analysis. Journal of the European Academy of Dermatology and Venereology : JEADV, 37(10), 1971–1990.
- Sheeran C, Nicolopoulos J. 2014. Pregnancy outcomes of two patients exposed to ustekinumab in the first trimester. Australasian J of Dermatology; 55(3);235-236.
- Wils P, et al. 2021. Safety of ustekinumab or vedolizumab in pregnant inflammatory bowel disease patients: a multicentre cohort study. Aliment Pharmacol Ther; 53(4):460-470.

¿Preguntas? Llame al 866.626.6847 | Texto 855.999.3525 | Correo electrónico o chat en MotherToBaby.org .

Descargo de responsabilidad: las hojas informativas de MotherToBaby están destinadas a fines de información general y no deben reemplazar los consejos de su proveedor de atención médica. MotherToBaby es un servicio de la Organización sin fines de lucro de Especialistas en Información de Teratología (OTIS). Copyright de OTIS, 1 de enero de 2025.